Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 6/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | CARM1 | Q86X55 | 3/20 | 0.30 |
| ▸ | LTA4H | P09960 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16120045 | 0.86 | TTK (0.39) | PRMT1SIGMAR1CARM1LTA4H | |
| SCHEMBL17469509 | 0.86 | PRMT1 (0.43) | PRMT1 | |
| SCHEMBL17469449 | 0.86 | PRMT1 (0.37) | PRMT1SIGMAR1CARM1 | |
| SCHEMBL17469497 | 0.85 | PRMT1 (0.38) | PRMT1SIGMAR1CARM1LTA4H | |
| SCHEMBL17469503 | 0.83 | PRMT1 (0.46) | PRMT1PRMT6CARM1 | |
| SCHEMBL17469508 | 0.82 | PRMT1 (0.41) | PRMT1PRMT6 | |
| SCHEMBL17469502 | 0.82 | LRRK2 (0.40) | — | |
| SCHEMBL17469504 | 0.81 | HTR2A (0.44) | PRMT1 | |
| SCHEMBL17469470 | 0.81 | HSP90AA1 (0.37) | PRMT1CARM1 | |
| SCHEMBL17469445 | 0.81 | FADS1 (0.40) | PRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180105497-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105497-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | PRMT1 1/4885PRMT6 4/4885SIGMAR1 3623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.